Medical - Instruments & Supplies
Build Your Comparison
Side-by-side financial analysisStock Comparison
NYXH vs INSP vs LIVN vs AVAV vs NVCR
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Devices
Aerospace & Defense
Medical - Instruments & Supplies
NYXH vs INSP vs LIVN vs AVAV vs NVCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Devices | Medical - Devices | Aerospace & Defense | Medical - Instruments & Supplies |
| Market Cap | $52M | $1.23B | $4.36B | $8.52B | $2.02B |
| Revenue (TTM) | $16M | $915M | $1.43B | $1.61B | $674M |
| Net Income (TTM) | $-86M | $131M | $107M | $-224M | $-173M |
| Gross Margin | 48.3% | 85.8% | 67.5% | 21.8% | 75.2% |
| Operating Margin | -5.3% | 5.6% | 13.4% | -8.3% | -27.2% |
| Forward P/E | — | 47.6x | 18.7x | 59.2x | — |
| Total Debt | $42M | $32M | $473M | $64M | $290M |
| Cash & Equiv. | $30M | $105M | $636M | $41M | $103M |
NYXH vs INSP vs LIVN vs AVAV vs NVCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 21 | Jun 26 | Return |
|---|---|---|---|
| Nyxoah S.A. (NYXH) | 100 | 5.8 | -94.2% |
| Inspire Medical Sys… (INSP) | 100 | 18.0 | -82.0% |
| LivaNova PLC (LIVN) | 100 | 93.5 | -6.5% |
| AeroVironment, Inc. (AVAV) | 100 | 154.6 | +54.6% |
| NovoCure Limited (NVCR) | 100 | 8.7 | -91.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NYXH vs INSP vs LIVN vs AVAV vs NVCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NYXH ranks third and is worth considering specifically for growth exposure.
- Rev growth 121.6%, EPS growth -30.9%, 3Y rev CAGR 48.1%
- 121.6% revenue growth vs NVCR's 8.3%
INSP carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 1.16
- Lower volatility, beta 1.16, Low D/E 4.1%, current ratio 6.08x
- Beta 1.16, current ratio 6.08x
- 14.3% margin vs NYXH's -5.3%
LIVN is the #2 pick in this set and the best alternative if value and momentum is your priority.
- Better valuation composite
- +70.3% vs NYXH's -81.6%
AVAV is the clearest fit if your priority is long-term compounding.
- 445.9% 10Y total return vs INSP's 70.9%
Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 121.6% revenue growth vs NVCR's 8.3% | |
| Value | Better valuation composite | |
| Quality / Margins | 14.3% margin vs NYXH's -5.3% | |
| Stability / Safety | Beta 1.16 vs NVCR's 2.21, lower leverage | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +70.3% vs NYXH's -81.6% | |
| Efficiency (ROA) | 15.2% ROA vs NYXH's -80.8%, ROIC 6.0% vs -76.4% |
NYXH vs INSP vs LIVN vs AVAV vs NVCR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
NYXH vs INSP vs LIVN vs AVAV vs NVCR — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
LIVN leads in 2 of 6 categories
INSP leads 1 • AVAV leads 1 • NYXH leads 0 • NVCR leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
LIVN leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AVAV is the larger business by revenue, generating $1.6B annually — 98.7x NYXH's $16M. INSP is the more profitable business, keeping 14.3% of every revenue dollar as net income compared to NYXH's -5.3%. On growth, NYXH holds the edge at +5.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $16M | $915M | $1.4B | $1.6B | $674M |
| EBITDAEarnings before interest/tax | -$81M | $62M | $220M | $82M | -$165M |
| Net IncomeAfter-tax profit | -$86M | $131M | $107M | -$224M | -$173M |
| Free Cash FlowCash after capex | -$73M | $97M | $161M | -$183M | -$48M |
| Gross MarginGross profit ÷ Revenue | +48.3% | +85.8% | +67.5% | +21.8% | +75.2% |
| Operating MarginEBIT ÷ Revenue | -5.3% | +5.6% | +13.4% | -8.3% | -27.2% |
| Net MarginNet income ÷ Revenue | -5.3% | +14.3% | +7.5% | -13.9% | -25.7% |
| FCF MarginFCF ÷ Revenue | -4.5% | +10.6% | +11.2% | -11.3% | -7.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +5.9% | +1.6% | +14.3% | +143.4% | +12.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +38.3% | -5.0% | +106.7% | -51.5% | -100.0% |
Valuation Metrics
LIVN leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 8.7x trailing earnings, INSP trades at a 92% valuation discount to AVAV's 110.1x P/E. On an enterprise value basis, LIVN's 17.4x EV/EBITDA is more attractive than AVAV's 104.4x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $52M | $1.2B | $4.4B | $8.5B | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $66M | $1.2B | $4.2B | $8.5B | $2.2B |
| Trailing P/EPrice ÷ TTM EPS | -0.51x | 8.73x | -17.84x | 110.05x | -14.57x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 47.59x | 18.68x | 59.24x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 17.83x | 17.39x | 104.43x | — |
| Price / SalesMarket cap ÷ Revenue | 4.48x | 1.35x | 3.14x | 10.38x | 3.09x |
| Price / BookPrice ÷ Book value/share | 0.93x | 1.63x | 3.61x | 5.42x | 5.82x |
| Price / FCFMarket cap ÷ FCF | — | 15.68x | 25.18x | — | — |
Profitability & Efficiency
INSP leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
INSP delivers a 18.0% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $-164 for NYXH. INSP carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to NYXH's 0.86x. On the Piotroski fundamental quality scale (0–9), INSP scores 7/9 vs NYXH's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -164.4% | +18.0% | +9.1% | -6.4% | -50.8% |
| ROA (TTM)Return on assets | -80.8% | +15.2% | +4.2% | -5.0% | -16.5% |
| ROICReturn on invested capital | -76.4% | +6.0% | +11.5% | +3.6% | -16.4% |
| ROCEReturn on capital employed | -80.4% | +6.7% | +10.2% | +4.5% | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 7 | 5 | 3 | 5 |
| Debt / EquityFinancial leverage | 0.86x | 0.04x | 0.39x | 0.07x | 0.85x |
| Net DebtTotal debt minus cash | $12M | -$73M | -$162M | $23M | $187M |
| Cash & Equiv.Liquid assets | $30M | $105M | $636M | $41M | $103M |
| Total DebtShort + long-term debt | $42M | $32M | $473M | $64M | $290M |
| Interest CoverageEBIT ÷ Interest expense | -32.73x | 418.58x | 5.18x | -5.99x | -96.80x |
Total Returns (Dividends Reinvested)
AVAV leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AVAV five years ago would be worth $15,065 today (with dividends reinvested), compared to $515 for NYXH. Over the past 12 months, LIVN leads with a +70.3% total return vs NYXH's -81.6%. The 3-year compound annual growth rate (CAGR) favors AVAV at 20.8% vs INSP's -48.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -69.1% | -53.7% | +30.9% | -33.4% | +35.5% |
| 1-Year ReturnPast 12 months | -81.6% | -66.8% | +70.3% | -10.3% | -2.3% |
| 3-Year ReturnCumulative with dividends | -82.4% | -85.9% | +65.4% | +76.1% | -59.8% |
| 5-Year ReturnCumulative with dividends | -94.9% | -77.3% | -2.8% | +50.6% | -91.9% |
| 10-Year ReturnCumulative with dividends | -94.2% | +70.9% | +62.7% | +445.9% | +62.1% |
| CAGR (3Y)Annualised 3-year return | -44.0% | -48.0% | +18.3% | +20.8% | -26.2% |
Risk & Volatility
Evenly matched — INSP and LIVN each lead in 1 of 2 comparable metrics.
Risk & Volatility
INSP is the less volatile stock with a 1.16 beta — it tends to amplify market swings less than NVCR's 2.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LIVN currently trades 98.3% from its 52-week high vs NYXH's 16.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.10x | 1.16x | 1.23x | 1.90x | 2.21x |
| 52-Week HighHighest price in past year | $8.59 | $147.03 | $80.73 | $417.86 | $18.92 |
| 52-Week LowLowest price in past year | $1.26 | $38.91 | $41.02 | $156.29 | $9.82 |
| % of 52W HighCurrent price vs 52-week peak | +16.2% | +29.0% | +98.3% | +40.8% | +94.0% |
| RSI (14)Momentum oscillator 0–100 | 25.8 | 43.3 | 69.4 | 49.4 | 57.1 |
| Avg Volume (50D)Average daily shares traded | 189K | 950K | 727K | 1.1M | 1.5M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: NYXH as "Buy", INSP as "Hold", LIVN as "Buy", AVAV as "Buy", NVCR as "Buy". Consensus price targets imply 331.7% upside for NYXH (target: $6) vs -0.2% for LIVN (target: $79).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $6.00 | $57.36 | $79.25 | $292.20 | $33.50 |
| # AnalystsCovering analysts | 5 | 27 | 14 | 28 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +14.2% | +0.1% | 0.0% | 0.0% |
LIVN leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). INSP leads in 1 (Profitability & Efficiency). 1 tied.
NYXH vs INSP vs LIVN vs AVAV vs NVCR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NYXH or INSP or LIVN or AVAV or NVCR a better buy right now?
For growth investors, Nyxoah S.
A. (NYXH) is the stronger pick with 121. 6% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Inspire Medical Systems, Inc. (INSP) offers the better valuation at 8. 7x trailing P/E (47. 6x forward), making it the more compelling value choice. Analysts rate Nyxoah S. A. (NYXH) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NYXH or INSP or LIVN or AVAV or NVCR?
On trailing P/E, Inspire Medical Systems, Inc.
(INSP) is the cheapest at 8. 7x versus AeroVironment, Inc. at 110. 1x. On forward P/E, LivaNova PLC is actually cheaper at 18. 7x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — NYXH or INSP or LIVN or AVAV or NVCR?
Over the past 5 years, AeroVironment, Inc.
(AVAV) delivered a total return of +50. 6%, compared to -94. 9% for Nyxoah S. A. (NYXH). Over 10 years, the gap is even starker: AVAV returned +445. 9% versus NYXH's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NYXH or INSP or LIVN or AVAV or NVCR?
By beta (market sensitivity over 5 years), Inspire Medical Systems, Inc.
(INSP) is the lower-risk stock at 1. 16β versus NovoCure Limited's 2. 21β — meaning NVCR is approximately 91% more volatile than INSP relative to the S&P 500. On balance sheet safety, Inspire Medical Systems, Inc. (INSP) carries a lower debt/equity ratio of 4% versus 86% for Nyxoah S. A. — giving it more financial flexibility in a downturn.
05Which is growing faster — NYXH or INSP or LIVN or AVAV or NVCR?
By revenue growth (latest reported year), Nyxoah S.
A. (NYXH) is pulling ahead at 121. 6% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: Inspire Medical Systems, Inc. grew EPS 179. 4% year-over-year, compared to -483. 6% for LivaNova PLC. Over a 3-year CAGR, NYXH leads at 48. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NYXH or INSP or LIVN or AVAV or NVCR?
Inspire Medical Systems, Inc.
(INSP) is the more profitable company, earning 15. 9% net margin versus -899. 1% for Nyxoah S. A. — meaning it keeps 15. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LIVN leads at 14. 4% versus -827. 8% for NYXH. At the gross margin level — before operating expenses — INSP leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NYXH or INSP or LIVN or AVAV or NVCR more undervalued right now?
On forward earnings alone, LivaNova PLC (LIVN) trades at 18.
7x forward P/E versus 59. 2x for AeroVironment, Inc. — 40. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NYXH: 331. 7% to $6. 00.
08Which pays a better dividend — NYXH or INSP or LIVN or AVAV or NVCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is NYXH or INSP or LIVN or AVAV or NVCR better for a retirement portfolio?
For long-horizon retirement investors, Inspire Medical Systems, Inc.
(INSP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 16)). Nyxoah S. A. (NYXH) carries a higher beta of 2. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INSP: +70. 9%, NYXH: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NYXH and INSP and LIVN and AVAV and NVCR?
These companies operate in different sectors (NYXH (Healthcare) and INSP (Healthcare) and LIVN (Healthcare) and AVAV (Industrials) and NVCR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: NYXH is a small-cap high-growth stock; INSP is a small-cap deep-value stock; LIVN is a small-cap quality compounder stock; AVAV is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.